NHF’s QMS is ISO 9001:2015 Certified

Government of Jamaica

NHF Increases Subsidy For Norvasc (Amlodipine) Used For The Treatment Of Hypertension And Ischaemic Heart Disease

NHF Increases Subsidy For Norvasc (Amlodipine) Used For The Treatment Of Hypertension And Ischaemic Heart Disease

The National Health Fund, NHF, has increased the subsidy for the active ingredient Amlodipine, which is used for the treatment of Hypertension and ischaemic heart disease.

The subsidy on a 5-milligram tablet has been increased from $6.01 to $38.97; and the subsidy on the 10-milligram tablet has been increased from $12.02 to $77.94.

These increases come against the background of the removal of generic alternatives from the market and a decision from the manufacturer of Norvasc the only brand available in Jamaica, to reduce the distributor prices of both strengths of Norvasc.

Mrs. Anne Logan, Individual Benefits Manager, NHF says, “Beneficiaries and pharmacists who have been making several requests to the NHF for increases in the subsidy should be happy at this good news from the NHF and the positive move by the manufacturer of Norvasc to lower their distributor price on the drug.”

National Health Fund © 2024. All Rights Reserved.